Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy.

Liao W, Lin JX, Leonard WJ.

Immunity. 2013 Jan 24;38(1):13-25. doi: 10.1016/j.immuni.2013.01.004. Review.

2.

Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.

Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, Moraga I, Raeber ME, Bowman GR, Novick P, Pande VS, Fathman CG, Boyman O, Garcia KC.

Nature. 2012 Mar 25;484(7395):529-33. doi: 10.1038/nature10975.

3.

Structural biology of shared cytokine receptors.

Wang X, Lupardus P, Laporte SL, Garcia KC.

Annu Rev Immunol. 2009;27:29-60. doi: 10.1146/annurev.immunol.24.021605.090616. Review.

4.

Detection of soluble interleukin-2 receptor and soluble intercellular adhesion molecule-1 in the effusion of otitis media with effusion.

Ganbo T, Hisamatsu KI, Inoue H, Kikushima K, Mizukoshi A, Murakami Y.

Mediators Inflamm. 1995;4(5):350-4.

5.

Interleukin-2 receptor beta chain as a possible target for low doses of mafosfamide.

Pukhalsky A, Toptygina A, Khaidukov S.

Mediators Inflamm. 1995;4(3):175-80.

6.

Elevation of soluble interleukin-2 receptor levels in nasal allergy.

Hisamatsu K, Ganbo T, Nakazawa T, Horiguchi S, Shimomura S, Murakami Y.

Mediators Inflamm. 1995;4(1):39-42.

7.

Biological significance of soluble IL-2 receptor.

Caruso C, Candore G, Cigna D, Colucci AT, Modica MA.

Mediators Inflamm. 1993;2(1):3-21.

8.

Interleukin 2: from immunostimulation to immunoregulation and back again.

Bachmann MF, Oxenius A.

EMBO Rep. 2007 Dec;8(12):1142-8. Review.

9.

Interleukin-2 receptor signaling in regulatory T cell development and homeostasis.

Burchill MA, Yang J, Vang KB, Farrar MA.

Immunol Lett. 2007 Nov 30;114(1):1-8. Review.

11.

Beta8 integrin binds Rho GDP dissociation inhibitor-1 and activates Rac1 to inhibit mesangial cell myofibroblast differentiation.

Lakhe-Reddy S, Khan S, Konieczkowski M, Jarad G, Wu KL, Reichardt LF, Takai Y, Bruggeman LA, Wang B, Sedor JR, Schelling JR.

J Biol Chem. 2006 Jul 14;281(28):19688-99.

12.

Requirement for Arf6 in breast cancer invasive activities.

Hashimoto S, Onodera Y, Hashimoto A, Tanaka M, Hamaguchi M, Yamada A, Sabe H.

Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6647-52.

13.

Binding of small molecules to an adaptive protein-protein interface.

Arkin MR, Randal M, DeLano WL, Hyde J, Luong TN, Oslob JD, Raphael DR, Taylor L, Wang J, McDowell RS, Wells JA, Braisted AC.

Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1603-8.

15.

Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor.

Sharfe N, Dadi HK, Shahar M, Roifman CM.

Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3168-71.

16.

Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes.

Loetscher P, Seitz M, Baggiolini M, Moser B.

J Exp Med. 1996 Aug 1;184(2):569-77.

17.
18.
19.

Role of protein glycosylation in immune regulation.

Hounsell EF, Davies MJ.

Ann Rheum Dis. 1993 Mar;52 Suppl 1:S22-9. Review. No abstract available.

20.

Requirements for the induction of the interleukin-2 receptor complex in a human pre-T-cell line.

Salvati PD, Peroni SE, Ranford PR, Kees UR.

Immunology. 1993 Mar;78(3):449-54.

Items per page

Supplemental Content

Support Center